Vaccibody is a clinical stage biopharmaceutical company that has developed its own proprietary vaccine technology platform for the treatment of cancer, pre-cancerous diseases and infectious diseases. Due to the modular structure of the vaccine, it easy to modify, making it uniquely suited for creating individualised vaccines, in addition to off the shelf vaccines, optimised to each type of disease. The company is currently pursuing two clinical research programs: VB10.16, a therapeutic HPV16 vaccine and VB10.NEO a cancer neoantigen vaccine specifically tailored to each patient.
There are significant opportunities for Vaccibody if the technology works. The biggest potential clearly is in treatment of cancers, but it also has potential as treatment of precancerous malignancies and infectious diseases.
The key risks with Vaccibody are related to clinical risk and the development of its candidates.
